These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30952820)

  • 1. The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.
    O'Kane GM; Su J; Tse BC; Tam V; Tse T; Lu L; Borean M; Tam E; Labbé C; Naik H; Mittmann N; Doherty MK; Bradbury PA; Leighl NB; Shepherd FA; Richard NM; Edelstein K; Shultz D; Brown MC; Xu W; Howell D; Liu G
    Oncologist; 2019 Jul; 24(7):e501-e509. PubMed ID: 30952820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.
    Jiang SX; Walton RN; Hueniken K; Baek J; McCartney A; Labbé C; Smith E; Chan SWS; Chen R; Brown C; Patel D; Liang M; Eng L; Sacher A; Bradbury P; Leighl NB; Shepherd FA; Xu W; Liu G; Hurry M; O'Kane GM
    Cancer Med; 2019 Dec; 8(18):7542-7555. PubMed ID: 31650705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
    Rangachari D; Yamaguchi N; VanderLaan PA; Folch E; Mahadevan A; Floyd SR; Uhlmann EJ; Wong ET; Dahlberg SE; Huberman MS; Costa DB
    Lung Cancer; 2015 Apr; 88(1):108-11. PubMed ID: 25682925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
    BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.
    Labbé C; Leung Y; Silva Lemes JG; Stewart E; Brown C; Cosio AP; Doherty M; O'Kane GM; Patel D; Cheng N; Liang M; Gill G; Rett A; Naik H; Eng L; Mittmann N; Leighl NB; Bradbury PA; Shepherd FA; Xu W; Liu G; Howell D
    Clin Lung Cancer; 2017 Jul; 18(4):388-395.e4. PubMed ID: 28111120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world disease burden and outcomes of brain metastases in
    Nadler E; Espirito JL; Pavilack M; Baidoo B; Fernandes A
    Future Oncol; 2020 Aug; 16(22):1575-1584. PubMed ID: 32495656
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites.
    Moskovitz M; Jao K; Su J; Brown MC; Naik H; Eng L; Wang T; Kuo J; Leung Y; Xu W; Mittmann N; Moody L; Barbera L; Devins G; Li M; Howell D; Liu G
    Curr Oncol; 2019 Dec; 26(6):e733-e741. PubMed ID: 31896943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data.
    Vedadi A; Shakik S; Brown MC; Lok BH; Shepherd FA; Leighl NB; Sacher A; Bradbury PA; Xu W; Liu G; O'Kane GM
    Qual Life Res; 2021 Feb; 30(2):445-454. PubMed ID: 32851601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study.
    Doherty MK; Leung Y; Su J; Naik H; Patel D; Eng L; Kong QQ; Mohsin F; Brown MC; Espin-Garcia O; Vennettilli A; Renouf DJ; Faluyi OO; Knox JJ; MacKay H; Wong R; Howell D; Mittmann N; Darling GE; Cella D; Xu W; Liu G
    Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29905764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer.
    Robin TP; Camidge DR; Stuhr K; Nath SK; Breeze RE; Pacheco JM; Liu AK; Gaspar LE; Purcell WT; Doebele RC; Kavanagh BD; Rusthoven CG
    J Thorac Oncol; 2018 May; 13(5):715-720. PubMed ID: 29269007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Suh JH; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Chao ST
    Pract Radiat Oncol; 2017; 7(4):e263-e273. PubMed ID: 28254368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
    Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
    J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
    Wrona A; Dziadziuszko R; Jassem J
    Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients.
    Mezquita L; Benito A; Ruano-Raviña A; Zamora J; Olmedo ME; Reguera P; Madariaga A; Villamayor M; Cortez SP; Gorospe L; Santón A; Mayoralas S; Hernanz R; Cabañero A; Auclin E; Carrato A; Garrido P
    Clin Lung Cancer; 2019 Jul; 20(4):305-312.e3. PubMed ID: 31151782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors.
    Yun PJ; Wang GC; Chen YY; Wu TH; Huang HK; Lee SC; Chang H; Huang TW
    PLoS One; 2019; 14(5):e0215923. PubMed ID: 31048854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
    Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
    J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
    Shin SM; Cooper BT; Chachoua A; Butler J; Donahue B; Silverman JS; Kondziolka D
    J Neurooncol; 2016 Feb; 126(3):483-91. PubMed ID: 26520640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
    Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
    Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.
    Sadoyama S; Sekine A; Satoh H; Iwasawa T; Kato T; Ikeda S; Sata M; Baba T; Tabata E; Minami Y; Nemoto K; Hayashihara K; Saito T; Okudela K; Ohashi K; Tajiri M; Ogura T
    Clin Lung Cancer; 2018 Jan; 19(1):e29-e36. PubMed ID: 28669848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
    Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
    J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.